Effect of Pre- and In-Hospital Delay on Reperfusion in Acute Ischemic Stroke Mechanical Thrombectomy.
odds ratio
reperfusion
thrombectomy
workflow
Journal
Stroke
ISSN: 1524-4628
Titre abrégé: Stroke
Pays: United States
ID NLM: 0235266
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
pubmed:
17
9
2020
medline:
11
11
2020
entrez:
16
9
2020
Statut:
ppublish
Résumé
Post hoc analyses of randomized controlled clinical trials evaluating mechanical thrombectomy have suggested that admission-to-groin-puncture (ATG) delays are associated with reduced reperfusion rates. Purpose of this analysis was to validate this association in a real-world cohort and to find associated factors and confounders for prolonged ATG intervals. Patients included into the BEYOND-SWIFT cohort (Bernese-European Registry for Ischemic Stroke Patients Treated Outside Current Guidelines With Neurothrombectomy Devices Using the Solitaire FR With the Intention for Thrombectomy; https://www.clinicaltrials.gov; Unique identifier: NCT03496064) were analyzed (n=2386). Association between baseline characteristics and ATG was evaluated using mixed linear regression analysis. The effect of increasing symptom-onset-to-admission and ATG intervals on successful reperfusion (defined as Thrombolysis in Cerebral Infarction [TICI] 2b-3) was evaluated using logistic regression analysis adjusting for potential confounders. Median ATG was 73 minutes. Prolonged ATG intervals were associated with the use of magnetic resonance imaging (+19.1 [95% CI, +9.1 to +29.1] minutes), general anesthesia (+12.1 [95% CI, +3.7 to +20.4] minutes), and borderline indication criteria, such as lower National Institutes of Health Stroke Scale, late presentations, or not meeting top-tier early time window eligibility criteria (+13.8 [95% CI, +6.1 to +21.6] minutes). There was a 13% relative odds reduction for TICI 2b-3 (adjusted odds ratio [aOR], 0.87 [95% CI, 0.79-0.96]) and TICI 2c/3 (aOR, 0.87 [95% CI, 0.79-0.95]) per hour ATG delay, while the reduction of TICI 2b-3 per hour increase symptom-onset-to-admission was minor (aOR, 0.97 [95% CI, 0.94-0.99]) and inconsistent regarding TICI 2c/3 (aOR, 0.99 [95% CI, 0.97-1.02]). After adjusting for identified factors associated with prolonged ATG intervals, the association of ATG delay and lower rates of TICI 2b-3 remained tangible (aOR, 0.87 [95% CI, 0.76-0.99]). There is a great potential to reduce ATG, and potential targets for improvement can be deduced from observational data. The association between in-hospital delay and reduced reperfusion rates is evident in real-world clinical data, underscoring the need to optimize in-hospital workflows. Given the only minor association between symptom-onset-to-admission intervals and reperfusion rates, the causal relationship of this association warrants further research. Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT03496064.
Sections du résumé
BACKGROUND AND PURPOSE
Post hoc analyses of randomized controlled clinical trials evaluating mechanical thrombectomy have suggested that admission-to-groin-puncture (ATG) delays are associated with reduced reperfusion rates. Purpose of this analysis was to validate this association in a real-world cohort and to find associated factors and confounders for prolonged ATG intervals.
METHODS
Patients included into the BEYOND-SWIFT cohort (Bernese-European Registry for Ischemic Stroke Patients Treated Outside Current Guidelines With Neurothrombectomy Devices Using the Solitaire FR With the Intention for Thrombectomy; https://www.clinicaltrials.gov; Unique identifier: NCT03496064) were analyzed (n=2386). Association between baseline characteristics and ATG was evaluated using mixed linear regression analysis. The effect of increasing symptom-onset-to-admission and ATG intervals on successful reperfusion (defined as Thrombolysis in Cerebral Infarction [TICI] 2b-3) was evaluated using logistic regression analysis adjusting for potential confounders.
RESULTS
Median ATG was 73 minutes. Prolonged ATG intervals were associated with the use of magnetic resonance imaging (+19.1 [95% CI, +9.1 to +29.1] minutes), general anesthesia (+12.1 [95% CI, +3.7 to +20.4] minutes), and borderline indication criteria, such as lower National Institutes of Health Stroke Scale, late presentations, or not meeting top-tier early time window eligibility criteria (+13.8 [95% CI, +6.1 to +21.6] minutes). There was a 13% relative odds reduction for TICI 2b-3 (adjusted odds ratio [aOR], 0.87 [95% CI, 0.79-0.96]) and TICI 2c/3 (aOR, 0.87 [95% CI, 0.79-0.95]) per hour ATG delay, while the reduction of TICI 2b-3 per hour increase symptom-onset-to-admission was minor (aOR, 0.97 [95% CI, 0.94-0.99]) and inconsistent regarding TICI 2c/3 (aOR, 0.99 [95% CI, 0.97-1.02]). After adjusting for identified factors associated with prolonged ATG intervals, the association of ATG delay and lower rates of TICI 2b-3 remained tangible (aOR, 0.87 [95% CI, 0.76-0.99]).
CONCLUSIONS
There is a great potential to reduce ATG, and potential targets for improvement can be deduced from observational data. The association between in-hospital delay and reduced reperfusion rates is evident in real-world clinical data, underscoring the need to optimize in-hospital workflows. Given the only minor association between symptom-onset-to-admission intervals and reperfusion rates, the causal relationship of this association warrants further research. Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT03496064.
Identifiants
pubmed: 32933420
doi: 10.1161/STROKEAHA.120.030208
pmc: PMC7523579
doi:
Banques de données
ClinicalTrials.gov
['NCT03496064']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2934-2942Références
J Neurointerv Surg. 2014 Mar;6(2):83-6
pubmed: 23390038
J Neurol Neurosurg Psychiatry. 2018 Sep;89(9):910-917
pubmed: 29519899
Cerebrovasc Dis. 2017;44(5-6):344-350
pubmed: 29130956
Cerebrovasc Dis. 2016;42(3-4):170-7
pubmed: 27111086
Stroke. 2017 Feb;48(2):348-352
pubmed: 28034965
Clin Neuroradiol. 2017 Mar;27(1):3-5
pubmed: 28124072
Stroke. 2019 Feb;50(2):365-372
pubmed: 30612537
Stroke. 2019 Mar;50(3):659-664
pubmed: 30744542
JAMA Neurol. 2019 Apr 1;76(4):405-411
pubmed: 30667465
J Neurol. 2019 Mar;266(3):598-608
pubmed: 30617997
Stroke. 2019 Dec;50(12):e344-e418
pubmed: 31662037
Sci Rep. 2017 Nov 21;7(1):15938
pubmed: 29162921
J Neurointerv Surg. 2019 May;11(5):433-438
pubmed: 30194109
J Neurointerv Surg. 2018 Dec;10(12):e30
pubmed: 29760012
Stroke. 2013 Oct;44(10):2802-7
pubmed: 23908066
Radiology. 2003 Jul;228(1):126-30
pubmed: 12728185
Stroke. 2017 Nov;48(11):3152-3155
pubmed: 29018132
J Neurointerv Surg. 2018 Apr;10(4):335-339
pubmed: 28754806
J Neurointerv Surg. 2019 Jan;11(1):9-13
pubmed: 29802163
Lancet. 1998 Oct 17;352(9136):1245-51
pubmed: 9788453
Stroke. 2013 Sep;44(9):2650-63
pubmed: 23920012